Keyword: Bexsero

After a study showed meningitis B vaccines can protect against gonorrhea, Bexsero maker GSK is weighing whether its vaccine can fight the disease.

GlaxoSmithKline's moms against meningitis B are back on the air in TV ads promoting its Bexsero vaccine for back-to-college.

While you’re packing to leave for school, get vaccinated against meningitis B, GSK urges students in a new awareness push.

GSK's Shingrix carried high expectations, but it turns out that even those ambitious projections weren't high enough.

The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.

Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.

While only in the very early stages of its important Shingrix launch, GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017.

Serum Institute of India plans to launch four vaccines in the coming years for pneumococcal, HPV, meningococcal and dengue.

For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas struggled.